Vontobel Holding Ltd. Makes New $262,000 Investment in Takeda Pharmaceutical Co. (NYSE:TAK)

Vontobel Holding Ltd. bought a new position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 17,619 shares of the company's stock, valued at approximately $262,000.

Other institutional investors have also added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at about $37,000. Farther Finance Advisors LLC increased its position in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $52,000. EverSource Wealth Advisors LLC increased its position in shares of Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after purchasing an additional 2,411 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Down 2.1%

TAK traded down $0.32 on Thursday, hitting $14.82. 975,145 shares of the company were exchanged, compared to its average volume of 1,988,700. The firm has a fifty day simple moving average of $14.86 and a two-hundred day simple moving average of $14.36. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.53. The stock has a market capitalization of $47.14 billion, a PE ratio of 67.39 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.